Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bis(5-Amidino-2-Benzimidazolyl)Methanone is an experimental small molecule compound with the molecular formula C17H14N8O and a molecular weight of approximately 346.3 g/mol[1][2][8]. It belongs to the class of aromatic diamidines and features two benzimidazole rings connected via a methanone (carbonyl) bridge. The compound has been studied primarily as an inhibitor of serine proteases, including tryptase and trypsin[4][10]. Its mechanism involves competitive inhibition at the active site of these enzymes, making it a potential lead for developing anticoagulant or anti-inflammatory agents[4][10]. However, there are no approved indications or advanced clinical trials for this molecule as of now; its use remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bis(5-Amidino-2-Benzimidazolyl)Methanone.